Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Promising therapeutic effects of sodium tanshinone IIA sulfonate towards pulmonary arterial hypertension in patients.

Wang J, Lu W, Wang W, Zhang N, Wu H, Liu C, Chen X, Chen Y, Chen Y, Jiang Q, Xu L, Tian L, Ran P, Zhong N.

J Thorac Dis. 2013 Apr;5(2):169-72. doi: 10.3978/j.issn.2072-1439.2013.02.04.

2.

Sodium tanshinone IIA sulfonate inhibits canonical transient receptor potential expression in pulmonary arterial smooth muscle from pulmonary hypertensive rats.

Wang J, Jiang Q, Wan L, Yang K, Zhang Y, Chen Y, Wang E, Lai N, Zhao L, Jiang H, Sun Y, Zhong N, Ran P, Lu W.

Am J Respir Cell Mol Biol. 2013 Jan;48(1):125-34. doi: 10.1165/rcmb.2012-0071OC.

3.

Isolation and structure characterization of related impurities in Sodium Tanshinone IIA Sulfonate by LC/ESI-MS(n) and NMR.

Wang B, Wang H, Wang E, Yan W, Ye W, Li P.

J Pharm Biomed Anal. 2012 Aug-Sep;67-68:36-41. doi: 10.1016/j.jpba.2012.04.029.

PMID:
22591803
4.
5.

Sodium tanshinone IIA sulfonate increased intestinal hemodynamics without systemic circulatory changes in healthy newborn piglets.

Liu J, Morton J, Miedzyblocki M, Lee TF, Bigam DL, Fok TF, Chen C, Lee SK, Davidge ST, Cheung PY.

Am J Physiol Heart Circ Physiol. 2009 Oct;297(4):H1217-24. doi: 10.1152/ajpheart.00477.2009.

6.

Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension.

Bharani A, Patel A, Saraf J, Jain A, Mehrotra S, Lunia B.

Indian Heart J. 2007 Jul-Aug;59(4):323-8.

PMID:
19126937
7.

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.

Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB; PACES Study Group..

Ann Intern Med. 2008 Oct 21;149(8):521-30. Erratum in: Ann Intern Med. 2009 Jan 6;150(1):63. Ann Intern Med. 2009 Sep 15;151(6):435.

PMID:
18936500
8.

Sodium tanshinone IIA sulfonate derived from Danshen (Salvia miltiorrhiza) attenuates hypertrophy induced by angiotensin II in cultured neonatal rat cardiac cells.

Takahashi K, Ouyang X, Komatsu K, Nakamura N, Hattori M, Baba A, Azuma J.

Biochem Pharmacol. 2002 Aug 15;64(4):745-9.

PMID:
12167494
9.
10.

Effects of sodium tanshinone II A sulphonate on hypoxic pulmonary hypertension in rats in vivo and on Kv2.1 expression in pulmonary artery smooth muscle cells in vitro.

Huang YF, Liu ML, Dong MQ, Yang WC, Zhang B, Luan LL, Dong HY, Xu M, Wang YX, Liu LL, Gao YQ, Li ZC.

J Ethnopharmacol. 2009 Sep 25;125(3):436-43. doi: 10.1016/j.jep.2009.07.020.

PMID:
19635545
11.

Tanshinone IIA: A Promising Natural Cardioprotective Agent.

Shang Q, Xu H, Huang L.

Evid Based Complement Alternat Med. 2012;2012:716459. doi: 10.1155/2012/716459.

12.

Sodium tanshinone IIA sulfonate and its interactions with human CYP450s.

Chen D, Lin XX, Huang WH, Zhang W, Tan ZR, Peng JB, Wang YC, Guo Y, Hu DL, Chen Y.

Xenobiotica. 2016 Dec;46(12):1085-1092.

PMID:
26932161
13.

The Minimal Important Difference in Borg Dyspnea Score in Pulmonary Arterial Hypertension.

Khair RM, Nwaneri C, Damico RL, Kolb T, Hassoun PM, Mathai SC.

Ann Am Thorac Soc. 2016 Jun;13(6):842-9. doi: 10.1513/AnnalsATS.201512-824OC.

PMID:
26974862
14.

Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.

McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W.

J Am Coll Cardiol. 2010 May 4;55(18):1915-22. doi: 10.1016/j.jacc.2010.01.027.

15.

Sodium tanshinone IIA sulfonate derived from Slavia miltiorrhiza Bunge up-regulate the expression of prolactin releasing peptide (PrRP) in the medulla oblongata in ovariectomized rats.

Xiao Y, Qing WX, Lan MS, Ying CB.

Biochem Pharmacol. 2006 Aug 28;72(5):582-7. Erratum in: Biochem Pharmacol. 2007 Feb 1;73(3):458. Xiaoa, Yao [corrected to Xiao, Yao].

PMID:
16846593
16.

Submaximal exercise testing may be superior to the 6-min walk test in assessing pulmonary arterial hypertension disease severity.

Neal JE, Lee AS, Burger CD.

Clin Respir J. 2014 Oct;8(4):404-9. doi: 10.1111/crj.12085.

PMID:
24308300
17.

Prevalence of pulmonary hypertension in patients with idiopathic pulmonary fibrosis: correlation with physiological parameters.

Papakosta D, Pitsiou G, Daniil Z, Dimadi M, Stagaki E, Rapti A, Antoniou K, Tzouvelekis A, Kontakiotis T, Tryfon S, Polychronopoulos V, Bouros D.

Lung. 2011 Oct;189(5):391-9. doi: 10.1007/s00408-011-9304-5.

PMID:
21660584
18.

The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension.

Bharani A, Mathew V, Sahu A, Lunia B.

Indian Heart J. 2003 Jan-Feb;55(1):55-9.

PMID:
12760589
19.

Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Marra AM, Egenlauf B, Ehlken N, Fischer C, Eichstaedt C, Nagel C, Bossone E, Cittadini A, Halank M, Gall H, Olsson KM, Lange TJ, Grünig E.

Int J Cardiol. 2015 Sep 15;195:19-26. doi: 10.1016/j.ijcard.2015.05.105.

20.

Effect of Supplementation of Tanshinone IIA and Sodium Tanshinone IIA Sulfonate on the Anticancer Effect of Epirubicin: An In Vitro Study.

Chan SE, Lai HW, Su CC, Kuo SJ, Chien SY, Lin HY, Chen DR.

Evid Based Complement Alternat Med. 2011;2011:841564. doi: 10.1155/2011/841564.

Supplemental Content

Support Center